| Literature DB >> 28733428 |
Alexandre Reuben1,2, Rachel Gittelman3, Jianjun Gao4, Jiexin Zhang5, Erik C Yusko3, Chang-Jiun Wu2, Ryan Emerson3, Jianhua Zhang2, Christopher Tipton3, Jun Li2, Kelly Quek2,6, Vancheswaran Gopalakrishnan1, Runzhe Chen2,6, Luis M Vence7, Tina Cascone6, Marissa Vignali3, Junya Fujimoto8, Jaime Rodriguez-Canales8, Edwin R Parra8, Latasha D Little2, Curtis Gumbs2, Marie-Andrée Forget9, Lorenzo Federico9, Cara Haymaker9, Carmen Behrens8, Sharon Benzeno3, Chantale Bernatchez9, Boris Sepesi10, Don L Gibbons6, Jennifer A Wargo1,2, William N William6, Stephen Swisher10, John V Heymach6, Harlan Robins3,11, J Jack Lee12, Padmanee Sharma4,7, James P Allison7, P Andrew Futreal13, Ignacio I Wistuba14, Jianjun Zhang13,6.
Abstract
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity.Significance: The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088-97. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28733428 PMCID: PMC5628137 DOI: 10.1158/2159-8290.CD-17-0256
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397